Daiichi Sankyo Remains Bullish On Prasugrel, Rivoglitazone Despite Safety Concerns – R&D Day
TOKYO - Daiichi Sankyo provided a status report to investors during a Feb. 21 research and development update in Tokyo. In particular, company officials responded to investor safety concerns related to two key pipeline drugs - anti-platelet drug prasugrel (CS-747) and rivoglitazone (CS-011), a PPAR agonist for type 2 diabetes
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
- • By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
- • By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
- • By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
- Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.






